Skip to main content
. 2017 Jun 15;57(3):355–365. doi: 10.1007/s40262-017-0562-0

Fig. 4.

Fig. 4

Pharmacokinetic model estimates across treatments. Comparison of individual CL (left) and V 1 (right) estimates in patients who received olaratumab as a single agent or in combination with either PTX and CP or Dox. CL clearance, CP carboplatin, Dox doxorubicin, PTX paclitaxel, V 1 central volume of distribution